OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Dreicer on the Different Approaches to mCRPC Management

April 18th 2024

Robert Dreicer, MD, discusses different approaches in prostate cancer management according to the type of oncologist.

Dr Jain on the Long-Term Investigation of Luspatercept in Anemic MDS

April 17th 2024

Akriti Jain, MD, discusses updated data from the phase 3 MEDALIST trial evaluating luspatercept for the treatment of anemic myelodysplastic syndromes.

Dr Srour on Toxicities Associated With CAR T-Cell Therapy in RCC and Other Solid Tumors

April 17th 2024

Samer A. Srour, MB ChB, MS, discusses toxicities associated with CTX130 in advanced clear cell renal cell carcinoma.

Dr Kristeleit on the ATHENA-MONO Trial in Ovarian Cancer

April 17th 2024

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the phase 3 ATHENA-MONO trial in newly diagnosed patients with advanced ovarian cancer.

Dr Foldi on the Evolving Role of T-DXd in HER2+ Breast Cancer

April 17th 2024

Julia Foldi, MD, PhD, discusses the evolving role of treatment with T-DXd in metastatic HER2-positive breast cancer.

Dr Guerra on a Culturally Tailored Approach to Prostate Cancer Screening Awareness

April 17th 2024

Carmen Guerra MD, MSCE, examines how a culturally sensitive could help raise prostate cancer screening awareness.

Dr Maxwell on a Study of Genetic Testing in Metastatic Prostate Cancer

April 17th 2024

Kara Maxwell, MD, PhD discusses a study of genetic testing results in metastatic prostate cancer.

Dr Sinno on Molecular Characterization in Endometrial Cancer

April 17th 2024

Abdulrahman Sinno, MD, discusses the shift in focus to molecular characteristics of endometrial cancer.

Dr Gatti-Mays on the Use of Neoadjuvant Chemoimmunotherapy in Early-Stage TNBC

April 16th 2024

Margaret E. Gatti-Mays, MD, MPH, FACP, discusses the current use of neoadjuvant chemoimmunotherapy in early-stage triple-negative breast cancer.

Dr Crane on the PRIMA Trial of Niraparib Maintenance Therapy in Ovarian Cancer

April 16th 2024

Erin K. Crane, MD, MPH, discusses the impact of the phase 3 PRIMA trial on second-line maintenance approaches in ovarian cancer.

Dr Hamid on the Use of Lifileucel in Advanced Melanoma

April 16th 2024

Omid Hamid, MD on adoptive T cell therapy, lifileucel, for patients with patients with advanced melanoma.

Dr Vallieres on the Role of Induction Therapy on Surgical Candidacy in Lung Cancer

April 16th 2024

Eric Vallieres, MD, FRCSC, discusses the impact of induction therapy on surgical candidacy and operative complexity in patients with thoracic malignancies.

Dr Piulats on Predictive Biomarkers for Treatment With Talazoparib/Enzalutamide in mCRPC

April 16th 2024

Josep Maria Piulats Rodriguez, MD, discusses an analysis evaluating predictive biomarkers for treatment with talazoparib plus enzalutamide in mCRPC.

Dr Srour on the Utility of CTX130 in RCC

April 16th 2024

Samer A. Srour, MB ChB, MS, discusses the utility of the CAR T-cell therapy CTX130 and unmet needs in advanced clear cell renal cell carcinoma.

Dr Pearse on the Utility of Pirtobrutinib in Relapsed/Refractory MCL

April 16th 2024

William B. Pearse, MD, discusses the current role of the BTK inhibitor pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.

Dr Agustí Garcia on the Rationale for the MELISA Trial in Ovarian Cancer

April 15th 2024

Núria Agustí Garcia, MD, discusses the MELISA trial, which is evaluating further steps toward lymphadenectomy replacement in ovarian cancer.

Dr Sekeres on the Rationale for the FDA Approval of Momelotinib in Myelofibrosis

April 15th 2024

Mikkael A. Sekeres, MD, MS, discusses the background on the FDA approval of momelotinib for the treatment of patients with anemic myelofibrosis.

Dr Levy on Multidisciplinary Treatment in Lung Cancer Care

April 15th 2024

Benjamin Levy, MD, discusses the utility of multidisciplinary treatment in lung cancer care.

Dr Ferrajoli on Shared Decision-Making During BTK Inhibitor Selection in Hematologic Malignancies

April 15th 2024

Alessandra Ferrajoli, MD, discusses the importance of shared decision-making when considering the use of BTK inhibitors in hematologic malignancies.

Dr Usmani on the Risk-Benefit Profile of Cilta-Cel in Relapsed/Refractory Multiple Myeloma

April 15th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the risk-benefit profile of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.